|
|
An analysis on the surveillance results of safety of post-marketing immunization of varicella attenuated live vaccine in Henan Province |
SHI Lu-bin,YANG Jian-hui,JI Yan-fang,LI Jun,YU Yan,YE Ying,ZHANG Yan-yang
|
Henan Provincial Center for Disease Control and Prevention,Zhengzhou,Henan,450016,China |
|
|
Abstract Objective To analyze the characteristics of adverse reactions for varicella attenuated live vaccine(VarV)in Henan Province from 2011 to 2016,in order to evaluate the immunization safety related to VarV. Methods The adverse reaction data and vaccination doses of VarV in Henan Province from 2011 to 2016 were collected through the China Information Management System for Immunization Programming. The descriptive methodology was used for data analysis. Results A total of 686 adverse reactions cases were reported in Henan Province from 2011 to 2016,and the average reported incidence rate was 16.89 per 100 000 dose. The ratio of male to female was 1.14∶1,and 80.61% cases occurred between 1 and 2 years old,and the reported incidence rate was 13.62 per 100 000 dose. And 32.80% cases were reported from April to June,and the reported incidence rate was 5.54 per 100 000 dose. The cases were mainly concentrated in Zhengzhou,Luoyang,Zhoukou and Xinyang. Most cases occurred after the first dose and within 1 d after vaccination. The main diagnoses of adverse reactions were fever,local swelling,indurations and transient anaphylactic disorders. The reported incidence rate of anaphylactic shock and fever convulsion were 0.37 per 100 000 dose and 0.12 per 100 000 dose respectively. All cases were recovered or got better. Conclusion The safety of VarV was good in Henan Province. However, the surveillance should focus on the anaphylactic shock and fever convulsion and other serious rare adverse reaction.
|
Received: 10 March 2017
Revised: 23 May 2017
Published: 10 October 2017
|
|
|
|
|
[1] 李兰娟,任红. 传染病学[M] . 8版. 北京:人民卫生出版社,2013:68-71. [2] World Health Organization. Varicella vaccines:WHO position paper,August 1998 [EB/OL] .[2017-02-28] . http://apps.who.int/iris/bitstream/10665/230537/1/WER7332_241-248.PDF. [3] 中华人民共和国卫生部,国家食品药品监督管理总局. 全国疑似预防接种异常反应监测方案[S] . 2010. [4] 叶莹,史鲁斌,李军,等. 河南省2009至2014年疑似预防接种异常反应监测分析[J] . 郑州大学学报(医学版),2016,51(2):258-262. [5] 潘雪娇,李倩,戚小华,等. 浙江省2013—2014年疑似预防接种异常反应监测数据分析[J] . 浙江预防医学,2015,27(11):1128-1130. [6] 叶家楷,李克莉,许涤沙,等. 中国2013年疑似预防接种异常反应信息管理系统数据分析[J] . 中国疫苗和免疫,2015,21(2):121-131. [7] 叶家楷,李克莉,许涤沙,等. 中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J] . 中国疫苗和免疫,2016,22(2):125-137. [8] 刘宇,赵占杰,谢莘,等. 广东省2005—2014年疑似预防接种异常反应监测数据分析[J] . 中国疫苗和免疫,2016,22(2):202-209,201. [9] 常琳,韩悦,姚文清. 辽宁省2009—2013年疑似预防接种异常反应监测分析[J] . 中国疫苗和免疫,2015,21(2):132-138,189. [10] WISE R P,SALIVE M E,BRAUN M M,et al. Postlicensure safety surveillance for varicella vaccine[J] . JAMA,2000,284(10):1271-1279. [11] 罗林云,刘小琴,马燕丽,等. 冻干水痘减毒活疫苗安全性及免疫原性观察[J] . 中国生物制品学杂志,2016,29(12):1298-1300. [12] 苏家立,黄竹航,陈海平,等. 国产冻干水痘减毒活疫苗加强免疫的免疫原性和安全性观察[J] . 中国疫苗和免疫,2016,22(4):366-370. [13] 潘雪娇,李倩,戚小华,等. 浙江省水痘减毒活疫苗安全性研究[J] . 中国预防医学杂志,2016,17(3):173-175. [14] 李兰馨,贺加. 国产水痘减毒活疫苗在中国人群中安全性和免疫原性的Meta分析[J] . 重庆医科大学学报,2013,38(6):662-667. [15] 杨洁,黄芳,林喜乐. 水痘减毒活疫苗两针法免疫效果及安全性评价[J] . 现代预防医学,2015,42(14):2630-2632. [16] GALEA S A,SWEET A,BENINGER P,et al. The safety profile of varicella vaccine:a 10-year review[J] . J Infect Dis,2008,197(2):165-169. [17] MAGLIONE M A,DAS L,RAAEN L,et al. Safety of vaccines used for routin immunization of US children:a systematic review[J] . Pediatrics,2014,134( 2):325-337. [18] 武文娣,李克莉,刘大卫,等. 中国2010—2012年水痘减毒活疫苗上市后安全性监测分析[J] . 中国疫苗和免疫,2014,20(1):13-18,35. [19] 武文娣,刘大卫,李克莉,等. 利用比例报告比方法分析中国2011—2013年水痘减毒活疫苗上市后预防接种异常反应信号[J] . 中国疫苗和免疫,2015,21(5):552-556,568. [20] 林辉荣,温瑞英. 1例接种水痘疫苗致过敏性休克的调查处置[J] . 海峡预防医学杂志,2014,20(3):95. [21] 杨万春. 接种水痘疫苗引起过敏性休克1例报告[J] . 职业卫生与病伤,2015,30(3):194-195. [22] 陶航. 水痘疫苗免疫策略研究[D] .长春:吉林大学,2015. [23] 吴根鹏,朱为. 水痘-带状疱疹疫苗的使用现状及研究进展[J] . 中国生物制品学杂志,2016,29(3):323-328,332. |
|
|
|